Study
Generalized myasthenia gravis (gMG) is an autoimmune condition that makes it harder for nerves to “talk” to muscles, leading to muscle weakness and fatigue that can come and go throughout the day. Symptoms can include, but are not limited to, drooping eyelids, double vision, trouble swallowing, difficulty breathing, fatigue, and weakness in your arms or legs. Even with treatment, many still deal with unpredictable symptoms and continuing fatigue.
What Is Generalized Myasthenia Gravis (gMG)?
About NMD670
NMD670 is an investigational oral medicine* (drug) being studied as a possible treatment for people with gMG.
It works differently from other gMG treatments by helping muscles respond to nerve signals. Early research suggests it may help muscles activate more effectively, even when signals from the nerves are weak. This could lead to improvements in muscle strength and reduce muscle fatigue. The purpose of this clinical trial is to learn how well different doses of the study drug work and how safe it is compared to a placebo. NMD670 may have the potential to provide meaningful improvements in muscle function across multiple types of gMG patients.
The study drug is taken as 2 tablets twice a day with water. It is expected to be used in addition to your current MG medications. These details should be discussed with your doctor.
In a previously completed placebo-controlled clinical trial in a small group of patients with gMG, patients received only a single dose of NMD670, and results demonstrated meaningful improvements in muscle strength for patients across multiple types of skeletal muscles (face, mouth/swallowing, arms, legs) throughout the body. Now, NMD Pharma and clinical researchers across a number of countries are testing NMD670 in this larger clinical trial to understand the safety and efficacy of the drug in various dosing levels over 21 days.
* An investigational drug is one that has not been approved by regulatory agencies, such as the United States (US) Food and Drug Administration (FDA), European Union (EU) European Medicines Agency (EMA), or others and can only be used in research studies.
3 Steps to Joining the
SYNAPSE-MG Clinical Trial
-
Find a convenient location
Look for a study site that works best for you.
-
Do you qualify for the study?
Answer a few simple questions to find out if you're eligible.
-
We'll be in touch
If you're eligible, someone from our team will reach out to answer your questions and help you schedule an appointment.
Clinical trials give hope. I felt proud to be part of medical advances.
Clinical Trial ParticipantAbout the gMG Clinical Trial
The purpose of this clinical trial is to study the safety and effects of NMD670 in adults with gMG.
What does participation include?
- Taking 2 tablets twice a day with water for 21 days
- You will be randomly assigned to receive 1 of 3 doses of NMD670 or placebo, with about 60% chance of receiving NMD670
- You will be required to attend 6 in-person study visits for up to an 8-week period
- You will be required to do a physical exam, some lab tests (including a blood draw), heart tests, nerve and muscle tests, and short questionnaires, and to complete a daily diary
What else should I know?
- Some participants will receive a placebo as part of the study design
- Participants can continue taking their current MG treatment(s)
- Travel costs will be reimbursed, with possible compensation for time or lost wages
- Participation could include a stipend of up to $300/per day for each day that a patient attends an in-clinic visit
- Participation is voluntary and at no cost
Who is eligible?
- Adults aged 18–75
- Those with a confirmed diagnosis of gMG with a positive antibody test for AChR or MuSK autoantibodies
- Those who are able to take tablets by mouth
See if You Qualify
Fields with * are required.
Fields with * are required.
